©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 7, 2015; 21(21): 6479-6490
Published online Jun 7, 2015. doi: 10.3748/wjg.v21.i21.6479
Published online Jun 7, 2015. doi: 10.3748/wjg.v21.i21.6479
Recent developments in pathogenesis, diagnosis and therapy of Barrett's esophagus
Magnus Halland, David Katzka, Prasad G Iyer, Division of Gastroenterology and Hepatology, Mayo Clinic Rochester, MN 55905, United States
Author contributions: Halland M contributed to literature review and drafting of manuscript; Katzka D contributed to drafting of manuscript and critical review of manuscript; Iyer PG contributed to drafting of manuscript and critical review of manuscript; all authors approved the final version of the manuscript.
Correspondence to: Prasad G Iyer, MD, Division of Gastroenterology and Hepatology, Mayo Clinic Rochester, Mayo Clinic, 200 First St. S.W., Rochester, MN 55905, United States. iyer.prasad@mayo.edu
Telephone: +1-507-2844824
Received: December 10, 2014
Peer-review started: December 11, 2014
First decision: January 8, 2015
Revised: January 31, 2015
Accepted: April 28, 2015
Article in press: April 28, 2015
Published online: June 7, 2015
Processing time: 183 Days and 9.7 Hours
Peer-review started: December 11, 2014
First decision: January 8, 2015
Revised: January 31, 2015
Accepted: April 28, 2015
Article in press: April 28, 2015
Published online: June 7, 2015
Processing time: 183 Days and 9.7 Hours
Core Tip
Core tip: This review highlights recent updates in the pathogenesis, diagnosis and therapy for Barrett’s esophagus (BE), the pre-malignant lesion for esophageal adenocarcinoma (EAC). The incidence of EAC continues to rise, and prognosis once diagnosed is poor. In this paper we critically reviewed the diagnostic criteria as well as new understanding of risk factors. Comparative recommendations from gastrointestinal societies are presented, and approaches to BE therapy, and management of recurrent BE after ablation is discussed.